Patents by Inventor Cheng Y. Chen

Cheng Y. Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200246410
    Abstract: Disclosed herein is the novel use of use of a Bauhinia spp. extract, which may upregulate neprilysin, induce autophagy, protect neuron from amyloidopathy or tauopathy, and/or promote neurite outgrowth, thus the Bauhinia spp. extract of the present disclosure may be used as a dietary supplement for the prophylaxis or treatment of amyloid related neurodegenerative diseases so as to ameliorate or alleviate symptoms associated with the amyloid related neurodegenerative diseases.
    Type: Application
    Filed: February 24, 2020
    Publication date: August 6, 2020
    Inventors: Chang-Jen HUANG, Rita P.-Y. CHEN, Yung-Feng LIAO, Bo-Kai WU, Po-Ting CHEN, Hui-Ping TSAI, Yi-Cheng CHENG, Cheng-Li FANG, Hung-Chi CHIEN, Tien-Soung TONG, Ting-Shou CHEN, Shu-Jiau CHIOU
  • Publication number: 20200176269
    Abstract: In an embodiment, a method includes: receiving, within a processing chamber, a wafer with a photoresist mask above a metal layer, wherein the processing chamber is connected to a gas source; applying an etchant configured to etch the metal layer in accordance with the photoresist mask within the processing chamber; and applying gas from the gas source to perform plasma ashing in the processing chamber.
    Type: Application
    Filed: November 14, 2019
    Publication date: June 4, 2020
    Inventors: Hsing-Hsiang WANG, Yu-Hsiang LIN, Wei-Da CHEN, Tom PENG, P.Y CHIU, Miau-Shing TSAI, Cheng-Yi HUANG, Ching-Horng CHEN
  • Patent number: 10610557
    Abstract: Disclosed herein is the novel use of use of a Bauhinia spp. extract, which may upregulate neprilysin, induce autophagy, protect neuron from amyloidopathy or tauopathy, and/or promote neurite outgrowth, thus the Bauhinia spp. extract of the present disclosure may be used as a dietary supplement for the prophylaxis or treatment of amyloid related neurodegenerative diseases so as to ameliorate or alleviate symptoms associated with the amyloid related neurodegenerative diseases.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: April 7, 2020
    Assignees: ACADEMIA SINICA, INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Chang-Jen Huang, Rita P.-Y. Chen, Yung-Feng Liao, Bo-Kai Wu, Po-Ting Chen, Hui-Ping Tsai, Yi-Cheng Cheng, Cheng-Li Fang, Hung-Chi Chien, Tien-Soung Tong, Ting-Shou Chen, Shu-Jiau Chiou
  • Publication number: 20200087850
    Abstract: Disclosed is a method of manufacturing a graphene conductive fabric, which includes mixing a first solvent, a second solvent and nano-graphene sheets, dispersing the nano-graphene sheets with a mechanical force to form a graphene suspension solution; adding at least a curable resin to the graphene suspension solution, dispersing the nano-graphene sheets and the curable resin with the mechanical force to form a graphene resin solution; coating or printing the graphene resin solution on a hydrophobic protective layer, curing the graphene resin solution to form a graphene conductive layer adhered to the hydrophobic protective layer; coating a hot glue layer on the graphene conductive layer; and attaching a fibrous tissue on the hot glue layer, heating and pressing the fibrous tissue to allow the hot glue layer respectively adhere to the graphene conductive layer and the fibrous tissue.
    Type: Application
    Filed: September 12, 2019
    Publication date: March 19, 2020
    Inventors: Mark Y. WU, Cheng-Yu HSIEH, Jing-Ru CHEN
  • Publication number: 20190316292
    Abstract: A graphene thermostatic fabric includes a fibrous tissue and a graphene thermostatic layer. The fibrous tissue has a first tissue surface, a second tissue surface and an interspace between the first tissue surface and the second tissue surface. The graphene thermostatic layer adheres to the first tissue surface, fills a part of the interspace, and includes at least a hydrophobic resin and nano-graphene sheets dispersed in the hydrophobic resin. A thermal conductivity of the graphene thermostatic layer varies with a change of an ambient temperature, and the thermal conductivity of the graphene thermostatic layer perpendicular to the first tissue surface is less than the thermal conductivity of the graphene thermostatic layer parallel to the first tissue surface. A method of manufacturing the graphene thermostatic fabric is further provided.
    Type: Application
    Filed: March 4, 2019
    Publication date: October 17, 2019
    Inventors: Mark Y. WU, Cheng-Yu HSIEH, Jing-Ru CHEN
  • Patent number: 10427942
    Abstract: A graphene dispersion paste has a viscosity in a range from 50,000 to 350,000 cps and a scraper fineness less than 20 ?m, and includes graphene sheets, a solvent and a first polymer, wherein the graphene sheets have a bulk density in a range from 0.005 to 0.05 g/cm3, a thickness in a range from 0.68 to 10 nm, and a plane lateral dimension in a range from 1 to 100 ?m. The present application further provides methods of preparing and using the graphene dispersion paste.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: October 1, 2019
    Assignee: ENERAGE INC.
    Inventors: Mark Y. Wu, Cheng-Yu Hsieh, Fang-Ru Shen, Geng Wei Lin, Jing-Ru Chen
  • Publication number: 20020107391
    Abstract: The present invention relates to a practical and efficient way to synthesize the compound for the endothelin receptor antagonist involving a Grignard addition and a cyclization reaction to give a desired compound of the general formula shown below: 1
    Type: Application
    Filed: October 18, 2001
    Publication date: August 8, 2002
    Inventors: Lisa F. Frey, Cheng Y. Chen, Jing Li, Zhiguo J. Song, Lushi Tan, Richard D. Tillyer, David M. Tschaen, Matthew M. Zhao
  • Patent number: 6281391
    Abstract: This invention encompasses a novel process for synthesizing compounds represented by formula A: These compounds are intermediates useful in the preparation of certain agents that are selective COX-2 inhibitors.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: August 28, 2001
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Richard D. Tillyer, Ian W. Davies, Robert D. Larsen, Xin Wang, Paul O'Shea, Anthony On-Ping King, Dalian Zhao, Cheng Y. Chen, Edward J. J. Grabowski
  • Patent number: 6140515
    Abstract: Described is a process of preparing 3-aryl, 4-aryloxy furan-5-ones which are useful as inhibitors of cyclooxygenase-2 (COX-2). Such compounds are useful as anti-inflammatory agents. The process is directed to an asymmetric synthesis which involves: a trisubstituted styrene derivative preparation via Horner-Wadsworth-Emmons reaction and subsequent one pot trifluoromethylation of the allylic alcohol; preparation of the .alpha.-hydroxyl ketone using Sharpless asymmetric dihydroxylation and Swern oxidation; the esterification of the .alpha.-hydroxyl ketone with the phenoxy acetic acid; and the Dieckman condensation of the resulting ester.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: October 31, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Cheng Y. Chen, Lushi Tan, Robert D. Larsen
  • Patent number: 6040480
    Abstract: The present invention provides novel methods for the asymmetric synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1- benzoxazin-2-one of formula (VI-i) ##STR1## which is useful as a human immunodeficiency virus (HIV) reverse transcriptase inhibitor.
    Type: Grant
    Filed: February 11, 1999
    Date of Patent: March 21, 2000
    Assignee: Du Pont Pharmaceuticals Company
    Inventors: Michael E. Pierce, Cheng Y. Chen, Anusuya Choudhury, Lilian A. Radesca, Lushi Tan, Dalian Zhao
  • Patent number: 5925789
    Abstract: The present invention provides novel methods for the asymmetric synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1- benzoxazin-2-one of formula (VI-i) ##STR1## which is useful as a human immunodeficiency virus (HIV) reverse transcriptase inhibitor.
    Type: Grant
    Filed: April 6, 1998
    Date of Patent: July 20, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Michael E. Pierce, Cheng Y. Chen, Anusuya Choudhury, Lilian A. Radesca, Lushi Tan, Dalian Zhao
  • Patent number: 5567824
    Abstract: A new process is described for the synthesis of the triazolyl tryptamine: ##STR1## and related compounds. The process involves a palladium-catalyzed ring closure between a substituted ortho-iodoaniline and a protected 1-alkynol. The process is carded out at high temperature, e.g. 100.degree. C., in a dry inert solvent, e.g., DMF and in the presence of a proton acceptor, e.g., Na.sub.2 CO.sub.3 or a trialkylamine. The triazolyl tryptamine, as well as acid addition salts thereof, is a 5 HT.sub.1 D receptor agonist having anti-migraine properties.
    Type: Grant
    Filed: May 24, 1994
    Date of Patent: October 22, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Cheng Y. Chen, Robert D. Larsen, Thomas R. Verhoeven